Funding for this research was provided by:
Hellenic Institute for the Study of Sepsis
Received: 17 July 2019
Accepted: 7 November 2019
First Online: 29 November 2019
Ethics approval and consent to participate
: Written informed consent was provided from all participants or their legal representatives. The derivation cohort resulted from a study approved by the Central Ethics Committee (EED), Athens, Greece (approval 42797/20-06-2007), and the National Organization for Medicines (EOF), Athens, Greece (approval 76305/15-02-2007), and was conducted according to the Declaration of Helsinki. EudraCT number 2006-004886-33. The validation cohort came from a study approved by the National Organization for Medicines of Greece (approval 14653/14-6-2004) that was conducted according to the Declaration of Helsinki.
: Not applicable
: E Karakike is funded by the Horizon 2020 Marie Skłodowska-Curie Grant European Sepsis Academy (grant 676129 paid to the University of Athens).EJ Giamarellos-Bourboulis has received honoraria (paid to the University of Athens) from AbbVie USA, Abbott CH, Biotest Germany, Brahms GmbH, InflaRx GmbH, the Medicines Company, MSD Greece, and XBiotech Inc. He has received independent educational grants from AbbVie, Abbott, Astellas Pharma, AxisShield, bioMérieux Inc., InflaRx GmbH, the Medicines Company, and XBiotech Inc. He has received funding from the FrameWork 7 program HemoSpec and from the Horizon 2020 Marie-Curie project European Sepsis Academy (granted to the National and Kapodistrian University of Athens), outside the submitted work.The other authors declare that they have no competing interests.